UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007234
Receipt number R000008526
Scientific Title The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.
Date of disclosure of the study information 2012/02/06
Last modified on 2012/06/27 11:49:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

Acronym

The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

Scientific Title

The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

Scientific Title:Acronym

The study of finding appropriate usage/dosage of peramivir on hemodialysis patient, an open-label study.

Region

Japan


Condition

Condition

hemodialysis patient

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the appropriate usage/dosage of peramivir by PK/PD in hemodialysis patient.

Basic objectives2

PK,PD

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

To evaluate the appropriate usage/dosage of peramivir.

Key secondary outcomes

None


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Other

Interventions/Control_1

Medication, Blood sampling for PK/PD

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with informed consent.
2) Age:over 20 years ( at the time the informed consent form is signed )
3) Gender: Male or female, In patients or Out patients.
4) Patients with regularly hemodialyzed.
5) Patients without influenza virus.

Key exclusion criteria

1) History of hypersensitivity, allergy or serious adverse drug event caused by oseltamivir phosphate, zanamivir hydrate, peramivir hydrate or raninanivir.
2)Patient with contraindications of 1) drugs.
3)Hepatic disorder.
4) Women who are pregnant or suspected to be pregnant and women who are breast-feeding.
5) Any other patients whose condition is inappropriate for the evaluation of this clinical study as judged by the investigator.

Target sample size

6


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Akiba

Organization

Tokyo Women's Medical University Hospital

Division name

Department of Bloods Purification, Kidney Center

Zip code


Address

8-1, Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan

TEL

03-3353-8111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Takashi Akiba

Organization

Tokyo Women's Medical University Hospital

Division name

Department of Bloods Purification, Kidney Center

Zip code


Address

8-1, Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

Tokyo Women's Medical University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京女子医科大学病院(東京都)


Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 10 Month 26 Day

Date of IRB


Anticipated trial start date

2012 Year 02 Month 01 Day

Last follow-up date

2012 Year 04 Month 01 Day

Date of closure to data entry

2012 Year 06 Month 01 Day

Date trial data considered complete

2012 Year 06 Month 01 Day

Date analysis concluded

2012 Year 07 Month 01 Day


Other

Other related information



Management information

Registered date

2012 Year 02 Month 06 Day

Last modified on

2012 Year 06 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008526


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name